P-glycoprotein Inhibitors Block Drug Efflux to Restore Chemotherapy Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy treatments face challenges with multidrug-resistant cancers due to the overexpression of P-glycoprotein, which effluxes chemotherapeutics, leading to reduced efficacy and increased toxicity, and the blood-brain barrier's P-glycoprotein limits drug penetration into the brain.
Innovation Solution
Development of inhibitor compounds that specifically target the ATP binding domains of P-glycoprotein, minimizing transport by the protein and blocking chemotherapeutic drug export, thereby re-sensitizing cancer cells to chemotherapy and enhancing drug penetration through barriers like the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If P-glycoprotein is overexpressed to efflux chemotherapeutics, then cancer cells develop multidrug resistance, but chemotherapeutic efficacy is reduced
Solution Approach 1:
The patent introduces P-glycoprotein inhibitor compounds as intermediary substances that block the efflux pump mechanism. These inhibitors bind to P-glycoprotein and prevent it from pumping chemotherapeutic drugs out of cancer cells, thereby reversing multidrug resistance and restoring chemotherapeutic efficacy without requiring modification of the chemotherapeutic agents themselves
Solution Approach 2:
The patent develops novel chemical compounds with specific molecular structures (including heterocyclic rings and specific functional groups) that have high affinity for P-glycoprotein binding sites. By changing the chemical parameters of the inhibitor molecules, the patent optimizes their ability to block P-glycoprotein function while minimizing transport by the protein itself
2Object-affected harmful factors
If P-glycoprotein is overexpressed at the blood-brain barrier, then drug penetration into the brain is limited, but protection from toxins is enhanced
Solution Approach 1:
The patent employs P-glycoprotein inhibitor compounds as mediators that temporarily block the efflux function at the blood-brain barrier. These inhibitors allow chemotherapeutic drugs to penetrate into the brain by preventing P-glycoprotein from pumping them back into the bloodstream, while the blood-brain barrier's protective function is restored after inhibitor clearance
Solution Approach 2:
The patent administers P-glycoprotein inhibitors prior to or during chemotherapeutic treatment to pre-block the efflux mechanism at the blood-brain barrier. This preliminary action creates a window of opportunity for enhanced drug penetration into the brain before P-glycoprotein function is restored
3Reliability
If conventional chemotherapeutics are used, then cancer cells are treated, but toxic side effects increase
Solution Approach 1:
The patent introduces P-glycoprotein inhibitors as intermediary agents that enable the use of conventional chemotherapeutics at potentially lower doses by reversing resistance mechanisms. This allows cancer treatment to proceed with improved efficacy while reducing the toxic burden on healthy tissues
Solution Approach 2:
The patent converts the harmful effect of P-glycoprotein-mediated drug efflux (which causes resistance) into a benefit by using selective P-glycoprotein inhibitors. These inhibitors specifically target the resistance mechanism while sparing the chemotherapeutic's anticancer activity, effectively turning the resistance pathway into a therapeutic opportunity
Data Source
AI summary
The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.